BBS-Bioactive Bone Substitutes Plc, Company Announcement, 31 August 2022 16.00 (CEST)
BBS Bioactive Bone Substitutes Oyj – Managers’ Transactions
____________________________________________
Person subject to the notification requirement
Name: Paananen, Ahti
Position: Member of the Board/Deputy member
Issuer: BBS Bioactive Bone Substitutes Oyj
LEI: 743700BYSBP0PCR6N767
Notification type: INITIAL NOTIFICATION
Reference number: 743700BYSBP0PCR6N767_20220826083437_4
____________________________________________
Transaction date: 2022-06-17
Venue not applicable
Instrument type: SHARE
ISIN: FI4000260583
Nature of the transaction: SUBSCRIPTION
Transaction details
(1): Volume: 166,689 Unit price: 1.3 EUR
Aggregated transactions
(1): Volume: 166,689 Volume weighted average price: 1.3 EUR
____________________________________________
Transaction date: 2022-06-20
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
ISIN: FI4000522909
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
Transaction details
(1): Volume: 20,836 Unit price: EUR
Aggregated transactions
(1): Volume: 20,836 Volume weighted average price: EUR
____________________________________________
Transaction date: 2022-06-20
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
ISIN: FI4000522891
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
Transaction details
(1): Volume: 20,836 Unit price: EUR
Aggregated transactions
(1): Volume: 20,836 Volume weighted average price: EUR
For more information:
Ilkka Kangasniemi, CEO,
tel. +35840 7080307, e-mail: ilkka.kangasniemi@bbs-artebone.fi
Liisa Hukka, CFO,
tel. +35840 0611038, e-mail: liisa.hukka@bbs-artebone.fi
Certified Advisor:
Nordic Certified Adviser AB, tel. +46 70 551 67 29, info@certifiedadviser.se
BBS in brief
BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi.
BBS-Bioactive Bone Substitutes Oyj:n shares have been listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
More information: www.bbs-artebone.fi
OAK BROOK, Ill., June 25, 2024 /PRNewswire/ -- Lions International celebrated several milestones during the…
Dr. Anthony Yanni publishes a wide-ranging case for patient-centered healthcare delivery and treatment development—a "long-overdue…
NEW YORK, June 25, 2024 /PRNewswire/ -- The Informatics Technology for Cancer Research (ITCR) program…
World's First AI to Detect 35 Cardiac Determinations, Including Heart Attack, Using a Reduced Leadset…
New service enhances access to high-quality and affordable virtual care throughout the Southeast. TAMPA, Fla.,…
Provides access to accurate patient insurance, demographic, and financial information for a better bottom line…